Platelet prothrombinase complex

The platelet prothrombinase complex is a high-efficiency enzymatic assembly that forms on the surface of activated platelets to drive the final stages of the blood coagulation cascade [1, 5]. It consists of the serine protease Factor Xa (the enzyme), Factor Va (the cofactor), calcium ions, and a negatively charged phospholipid surface, such as phosphatidylserine, which is exposed on the outer leaflet of the platelet membrane upon activation [1, 12]. The assembly of this complex is a critical regulatory step, as it enhances the rate of prothrombin-to-thrombin conversion by approximately 300,000-fold compared to the action of Factor Xa alone [5, 13]. Thrombin generated by this complex is the primary effector of hemostasis, responsible for fibrin formation and further platelet activation [2, 7]. Because of its central role in both physiological hemostasis and pathological thrombosis, the prothrombinase complex—specifically its Factor Xa component—is a major target for modern anticoagulant therapies, including direct oral anticoagulants (DOACs) like rivaroxaban and apixaban [5, 9]. While these drugs are highly effective in preventing conditions such as stroke and venous thromboembolism, their use is associated with a significant risk of bleeding, necessitating careful clinical management and the development of specific reversal agents [11, 17].

Other names

ProthrombinaseFactor Va-Factor Xa complexFXa-FVa complexPlatelet-associated prothrombinase

The prothrombinase complex catalyzes the proteolytic conversion of prothrombin (Factor II) into active thrombin (Factor IIa) by cleaving peptide bonds at Arg271 and Arg320. Drugs targeting this complex primarily inhibit the enzymatic activity of Factor Xa or reduce the availability of its constituent factors.